Pfizer deals extend patent life for a top-selling rare disease drug

<figure><div><img src="https://imgproxy.divecdn.com/jQ_5Zg_Ho64m_MJfxtpQ3m-Akr_tdECWcnW-WlOnR2g/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDkxNDg0MDMxLmpwZw==.webp"/></div></figure><p>Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam. </p>

Ben Fidler · 2026-04-30

Pfizer deals extend patent life for a top-selling rare disease drug

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.

Source: PharmaVoice